(lp0
S"Progenics Pharmaceuticals, Inc. to Participate in February Investor Conferences GlobeNewswire  - Feb 8, 2017 NEW YORK, Feb. 08, 2017  -- Progenics Pharmaceuticals, Inc. , an oncology company developing innovative medicines and other technologies for targeting and treating cancer, today announced that Mark Baker, Chief&nbsp;...Noticeable Analyst's Ideas: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX ... - TRA"
p1
aS"Buy or Sell? What Analysts Recommends: Sunrun Inc. , Progenics ... StockNewsJournal - 19 hours ago Progenics Pharmaceuticals, Inc. , maintained return on investment for the last twelve months at 7.06, higher than what Reuters data shows regarding industry's average.Why Analysts put forward these two stocks: Progenics Pharmaceuticals, Inc ... - The USA CommerceProgenics Pharmaceuticals, Inc. : Thoughts on the Momentum - Post Analyst"
p2
aS"Why Progenics Pharmaceuticals, Inc. Is Rising Today Motley Fool - Oct 4, 2016 It certainly is an exciting time to be an investor in Progenics. The company and its partner Valeant Pharmaceuticals  just launched an oral version of their opioid-induced constipation  drug Relistor in the third quarter. While the drug ...Brean Capital Assumes Buy on Progenics Pharmaceuticals, Inc. ; Sees 50 ... - Smarter AnalystProgenics Pharma : Profitability Could Come In '17 - Needham - StreetInsider.com"
p3
aS"Why Progenics Pharmaceuticals, Inc. Shares Soared Today Motley Fool - Jul 20, 2016 What: Progenics Pharmaceuticals  is up 23% at 3:35 p.m. ET after announcing yesterday after the closing bell that the Food and Drug Administration approved an oral version of the company's opioid-induced constipation drug, Relistor.Brean Capital Sees 125% Upside for Progenics Pharmaceuticals, Inc. (PGNX ... - Smarter AnalystValeant Pharma , Progenics Pharmaceuticals  Granted FDA Approval ... - StreetInsider.com"
p4
aS'Why Progenics Pharmaceuticals, Inc. Stock Climbed 76.5% in November Motley Fool - Dec 6, 2016 Shares of Progenics Pharmaceuticals, Inc. , a small biotech with an oncology focus, rocketed up 76.5% in November, according to data from S&amp;P Global Market Intelligence.'
p5
aS"Progenics Pharmaceuticals: 25% Upside Left After 60% Move? Seeking Alpha - Nov 20, 2016 My yearlong patience with Progenics Pharmaceuticals  finally seems to be finally paying off in spades. The stock has moved up some 60% so far in the month of November as investors finally appear to be recognizing the company's value and&nbsp;..."
p6
aS'Option Market Alert: Progenics Pharmaceuticals Inc Implied Price Swing Hits An ... CML News - Mar 19, 2017 Risk Alert: Before we dive into any analysis we simply note that Progenics Pharmaceuticals Inc  risk is elevated.'
p7
aS'Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial ... GlobeNewswire  - Feb 23, 2017 NEW YORK, Feb. 23, 2017  -- Progenics Pharmaceuticals, Inc., , an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference&nbsp;...Stock Price of Progenics Pharmaceuticals Inc.  Increases 11.56% - Energy IndexAn End-of-Day Technical Review: Progenics Pharmaceuticals, Inc. (PGNX ... - Post Analyst'
p8
aS'Stocks Favored By Analysts: Progenics Pharmaceuticals, Inc.  Iao ... Rives Journal - 16 hours ago Sell-side analysts are offering a consensus Buy rating on shares of Progenics Pharmaceuticals, Inc. .'
p9
aS'Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 ... Yahoo Finance - Mar 9, 2017 NEW YORK, March 09, 2017  -- Progenics Pharmaceuticals, Inc.  today announced financial results and provided a business update for the fourth quarter and full-year 2016.'
p10
a.